Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses RNAi Patents from Alnylam to Sell Research Products, Services

NEW YORK, June 9 (GenomeWeb News) - Alnylam Pharmaceutials has licensed its short interfering RNA technology patents to Ambion to provide research products and services, the companies said yesterday.

 

The non-exclusive license comprises use of the Kreutzer-Limmer patent family, owned by Alnylam, which cover siRNAs and their use to mediate RNA interference in mammalian cells.

 

Ambion is the fifth research products supplier, and the tenth company in total, to take a license to the patent estate from Alnylam, according to the company. The original Kreutzer-Limmer patent is currently opposed in Europeby a number of companies.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.